Skip to content
Home/Companies/MedTech/Avedro

Avedro

MedTech·US·Exited 2019·Held 5yr
Entry
2014
Hold
5yr
Exit
2019

Who owns Avedro?

Avedro was owned by Abingworth through Abingworth Bioventures VI (2014 vintage) from 2014 to 2019, exited via Trade Sale.

Buyer identity available on Pro.

Hand-verified · updated 2026-05-21

Abingworth
Investor
Abingworth
Abingworth Bioventures VI · 2014 · Life Sciences VC

Key facts

HQUS
SectorMedTech
StatusAcquired
Exit Type
Trade Sale
Buyer
MOIC
–
Exit Year
2019

More from Abingworth Bioventures VI

Other portfolio companies in the same fund.

Verona Pharma
Verona Pharma
Exited 2025
BiotechUK
to
Venatorx Pharmaceuticals
Venatorx Pharmaceuticals
Active
HealthcareUS· 2022
Exicure
Active
BiotechUS· 2019
Soleno Therapeutics
Soleno Therapeutics
Exited 2026
BiotechUS· 2018
to
Tizona Therapeutics
Tizona Therapeutics
Active
BiotechUS· 2016
Median Technologies
Active
MedTechFrance· 2015

More PE-backed in MedTech

Comparable medtech deals from other GPs.

Acufocus, Inc.
Exited 2023
The Carlyle GroupUS
to
Adicon Holdings Limited
Active
The Carlyle GroupUS
Aesynt
Exited 2016
Francisco PartnersUS
to
Alere Medical, Inc.
Active
TA AssociatesUS
Alma Lasers, Ltd.
Alma Lasers, Ltd.
Active
TA AssociatesIsrael
Amedes Group
Active
General AtlanticGermany
Track Avedro

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Who could buy Avedro?

7 strategic and 113financial buyers match this company's sector and geography profile, ranked from verified European deal history.

Find likely buyers

Get the full record on Avedro.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyer and MOIC on this deal (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue